Virus targets
Hepatitis B
Testing and treatment implementation
Health outcomes
WHO region
South-East Asia Region
Western Pacific Region
Key interventions
Community mobilization
Hepatitis B Vaccination
Prevention mother-child transmission
Strategic data analysis
Testing and diagnosis
Treatment (direct or referral)
Target population
Adults (> 19 years of age)
Performance target
Care cascade: Evidence of current infection
Care cascade: HBV diagnosis
Care cascade: HBV testing
Care cascade: HBV treatment
Care cascade: Referred for treatment
HBV prevention of mother to child transmission
Hepatitis B vaccination coverage
If you would like to have a program page for your program, please create an account and submit program information here

Health outcomes additional info

We align our work with the UN SDGs and contribute to the following targets set in the 2015 agenda: 3.3: Combating viral hepatitis; 3.3: Increasing access to vaccination; 8.5: Achieve full and productive employment for all women and men, including people with disabilities; 9.1: Develop quality, reliable, sustainable and resilient infrastructure […] to support economic development and human well-being, with a focus on affordable and equitable access for all; 10.2: Empower and promote the social, economic and political inclusion of all, irrespective of […] disability; 10.3: Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard.

Performance target additional info

Besides facilitating access to healthcare, we also focus on increasing general awareness of HBV as a national health concern, combating workplace discrimination of HBV carriers, and social stigmatization.

Summary and objectives

GOViral aims to break the cycle of hepatitis B transmission in the Philippines. We advocate for greater awareness of HBV at all levels of Filipino society and governance, and fight against the widespread economic discrimination and social stigmatization faced by HBV carriers. We developed a 3-tiered solution focused on Awareness, Advocacy, and Access.

Although vaccines, tests, and medication exist, these are not reaching those who need them. As this is a supply chain failure, it demands an infrastructure-oriented solution. Our Access solution consists of a two-tiered integrated infrastructure developed in consultation with experts, healthcare workers, and Filipino patients. The first Access tier connects HBV carriers to healthcare and establishes a cycle of care by automating the full user journey. This ranges from facilitating access to testing for a person of unknown HBV status, to integrated care for a HBV+ patient requiring regular viral load and liver function monitoring to possible treatment. The second Access tier ensures seamless integration into a fully automated supply chain that integrates the ordering, sourcing, and distribution of testing and treatment products from pharmaceutical companies. Importantly, working with and within the community, we recognize heterogeneity of technology penetration in urban and rural areas, and combine tailored online and offline solutions.

Access to healthcare in the Philippines is complicated by two key factors: geography and governance. The Philippine archipelago comprises 7,641 islands with up to 187 distinct languages and dialects. Governance is highly decentralised and healthcare funding varies widely at the regional, municipal, and community level: the WHO defined the Filipino healthcare system as "fragmented", meaning there is a large quality and quantity gap for health services. Thus, to improve access to care, the individual healthcare units need to be connected better, and secondly, the Filipino market is challenging for pharmaceutical companies with its high cost of entry and low purchasing power. Our GOViral infrastructure integrates health services with the pharmaceutical supply chain, offering pain-free access to the Filipino market. An estimated 90% of patients are unaware of their status and not availing of healthcare, and our community research showed that among those aware of their HBV, almost 27% was not under observation by a doctor for monitoring, which is essential to monitor disease progression. Thus, we not only expand the market in absolute numbers of patients reached, but also establish repeat purchases by automating the cycle of care that HBV patients need.

To bridge the gap between individual and healthcare in rural areas, we engage community healthcare coordinators that carry trust and authority. Embedding our digital solution into their networks allows us to bridge the last mile. Importantly, as all possible user journeys for hepatitis are known, we can digitise and streamline the decision-making process so that they can coordinate patient care without requiring specific expertise. In urban areas, citizens generally have access to a local healthcare unit directly. We engage these units through our awareness programme, or in the bigger cities where individuals are used to organizing their healthcare through online platforms, engage individuals directly.

Last updated